University of Colorado

National Jewish Health

National Institutes of Health, a Component of the US Dept. of Health & Human Services

National Jewish Medical and Research Center

Nepenthe Bioscience LLC

John C Cambier

Yosef Refaeli

Brian Curtis Turner

Sara Ann Johnson

Barbara J Vilen

James W Larrick

Bo Yu

Andrew Mendelsohn

Elizabeth Franks

Methods of using a phosphoinositide 3-kinase p110-delta inhibitor to treat, delay the onset, or slow the progression of an autoimmune disease or disorder in a subject, without suppressing the subject's B cell responses to exogenous antigens or rendering the subject immunocompromised, as well as pharmaceutical compositions containing phosphoinositide 3-kinase p110-delta inhibitors in amounts suitable for convenient and accurate administration within these therapeutic methods.

p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens

The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.

Anti-CD79 antibodies and their uses

Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.

Conditionally immortalized long-term stem cells and methods of making and using such cells

Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells

Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.

Product and method for treatment of conditions associated with receptor-desensitization

Method for receptor desensitization

Growing community of inventors

Denver, CO, United States of America

John C Cambier